Date:2/3/2009

4,687 (2,769) Share-based consulting expense 52,567 37,942 Share-based compensation expense 583,013 829,146 Deferred income taxes (11,531) 7,113 Deferred rent (26,250) (26,250) Changes in operating assets and liabilities: Accounts receivable 668,510 (534,542) Inventories (34,427) 64,390 Other current assets and income tax receivable 8,173 191,921 Accounts payable (91,686) 94,198 Accrued liabilities (802,027) 312,158 Accrued pension liability, net (7,585) (247,388) Net cash used in operating activities (668,157) (1,603,028) Cash flows from investing activities: Proceeds from sale of short-term investments 14,157,410 4,200,000 Purchase of short-term investments (7,891,373) (3,648,447) Purchases of property, plant and equipment (181,354) (210,875) Proceeds from sale of equipment - 4,811 Payments for intangible assets (23,282) (92,013) Net cash provided by investing activities 6,061,401 253,476 Cash flows from financing activities: Proceeds from financing obligations - 178,374 Repayment of debt obligations (455,913) (239,872) Net proceeds from issuance of common stock, warrants and option exercise - 5,374,233 Net cash provided by (used in) financing activities (455,913) 5,312,735 Effect of exchange rates
'/>"/>

SOURCE Uroplasty, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers